Vaxart Oral Vaccine Description
Vaxart has announced the initiation of a development program to develop an oral vaccine targeting the novel coronavirus 2019-nCoV
This development effort is based on the oral vaccine platform, VAAST.
“The results of our recently published influenza challenge study demonstrated that our oral tablet vaccine primarily protects through mucosal immunity, a potential key factor when targeting mucosal pathogens, such as this new coronavirus,” said Sean Tucker, Ph.D. chief scientific officer of Vaxart.
Vaxart Oral Vaccine Indication
This Oral vaccine candidate would be indicated to prevent the new coronavirus known as 2019-nCoV.
Vaxart Oral Vaccine Dosage
An oral vaccine administered using a room temperature-stable tablet could be of logistical and critical benefit during major public health vaccination campaigns.